FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017005150> ?p ?o ?g. }

• W2017005150 endingPage "1554" @default.
• W2017005150 startingPage "1544" @default.
• W2017005150 abstract "The authors explored the association of skin toxicity (ST) severity as measured by patient-reported ST and Common Terminology Criteria for Adverse Events (CTCAE) grading with efficacy of panitumumab, a fully human antiepidermal growth factor receptor antibody, from a phase 3 metastatic colorectal cancer (CRC) trial.Patients were randomized to panitumumab plus best supportive care (BSC) vs BSC alone. ST by modified National Cancer Institute CTCAE v3.0 and modified Dermatology Life Quality Index (mDLQI), health-related quality of life (HRQOL), and CRC symptoms were measured. ST was analyzed using a landmark approach. Associations by KRAS mutational status were also assessed.Of 463 patients, 208 of 231 (90%) panitumumab patients and 184 of 232 (79%) BSC patients had > or = 1 postbaseline patient-reported outcome (PRO) assessment. Panitumumab patients with more severe ST had significantly longer overall survival (OS) (grade 2-4:grade 1; hazard ratio, 0.60; P = .0033). Lower mDLQI scores (< 67; more bothersome ST) were associated with longer OS (Cox model, P < .0001). Similar results were observed with progression-free survival (PFS). An inverse relation between mDLQI and HRQOL scores was observed, suggesting that ST bother correlated with better HRQOL. KRAS and PRO data were available in 363 patients (188 panitumumab; 175 BSC). Longer OS was associated with lower mDLQI scores, regardless of KRAS status. Longer PFS was associated with more severe ST (lower mDLQI scores and higher CTCAE grade ST) in patients with wild-type (WT) KRAS tumors, but not in patients with mutant KRAS tumors.More severe ST, by both clinical grading and PRO, is associated with better CRC symptoms and HRQOL and with longer OS and PFS among panitumumab-treated patients. The associations for PFS were more pronounced in patients with WT KRAS tumors." @default.
• W2017005150 created "2016-06-24" @default.
• W2017005150 creator A5010633245 @default.
• W2017005150 creator A5011308487 @default.
• W2017005150 creator A5011662854 @default.
• W2017005150 creator A5020450763 @default.
• W2017005150 creator A5031031537 @default.
• W2017005150 creator A5042028913 @default.
• W2017005150 creator A5060058983 @default.
• W2017005150 creator A5060795077 @default.
• W2017005150 creator A5069521698 @default.
• W2017005150 creator A5090645179 @default.
• W2017005150 date "2009-04-01" @default.
• W2017005150 modified "2023-09-25" @default.
• W2017005150 title "Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and<i>KRAS</i>status in patients receiving panitumumab monotherapy" @default.
• W2017005150 cites W1488694215 @default.
• W2017005150 cites W1912318374 @default.
• W2017005150 cites W1968151389 @default.
• W2017005150 cites W1992292837 @default.
• W2017005150 cites W2011513069 @default.
• W2017005150 cites W2015618811 @default.
• W2017005150 cites W2018727601 @default.
• W2017005150 cites W2019195072 @default.
• W2017005150 cites W2020830322 @default.
• W2017005150 cites W2026836992 @default.
• W2017005150 cites W2042450112 @default.
• W2017005150 cites W2051120695 @default.
• W2017005150 cites W2094993869 @default.
• W2017005150 cites W2096991001 @default.
• W2017005150 cites W2097121246 @default.
• W2017005150 cites W2106789440 @default.
• W2017005150 cites W2106983577 @default.
• W2017005150 cites W2119523268 @default.
• W2017005150 cites W2121368761 @default.
• W2017005150 cites W2128447158 @default.
• W2017005150 cites W2140510616 @default.
• W2017005150 cites W2142564546 @default.
• W2017005150 cites W2157769714 @default.
• W2017005150 cites W2167571044 @default.
• W2017005150 cites W2168213749 @default.
• W2017005150 cites W2168377135 @default.
• W2017005150 cites W2502806512 @default.
• W2017005150 doi "https://doi.org/10.1002/cncr.24088" @default.
• W2017005150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19189371" @default.
• W2017005150 hasPublicationYear "2009" @default.
• W2017005150 type Work @default.
• W2017005150 sameAs 2017005150 @default.
• W2017005150 citedByCount "120" @default.
• W2017005150 countsByYear W20170051502012 @default.
• W2017005150 countsByYear W20170051502013 @default.
• W2017005150 countsByYear W20170051502014 @default.
• W2017005150 countsByYear W20170051502015 @default.
• W2017005150 countsByYear W20170051502016 @default.
• W2017005150 countsByYear W20170051502017 @default.
• W2017005150 countsByYear W20170051502018 @default.
• W2017005150 countsByYear W20170051502019 @default.
• W2017005150 countsByYear W20170051502020 @default.
• W2017005150 countsByYear W20170051502021 @default.
• W2017005150 countsByYear W20170051502022 @default.
• W2017005150 crossrefType "journal-article" @default.
• W2017005150 hasAuthorship W2017005150A5010633245 @default.
• W2017005150 hasAuthorship W2017005150A5011308487 @default.
• W2017005150 hasAuthorship W2017005150A5011662854 @default.
• W2017005150 hasAuthorship W2017005150A5020450763 @default.
• W2017005150 hasAuthorship W2017005150A5031031537 @default.
• W2017005150 hasAuthorship W2017005150A5042028913 @default.
• W2017005150 hasAuthorship W2017005150A5060058983 @default.
• W2017005150 hasAuthorship W2017005150A5060795077 @default.
• W2017005150 hasAuthorship W2017005150A5069521698 @default.
• W2017005150 hasAuthorship W2017005150A5090645179 @default.
• W2017005150 hasBestOaLocation W20170051501 @default.
• W2017005150 hasConcept C121608353 @default.
• W2017005150 hasConcept C126322002 @default.
• W2017005150 hasConcept C143998085 @default.
• W2017005150 hasConcept C159110408 @default.
• W2017005150 hasConcept C197934379 @default.
• W2017005150 hasConcept C207103383 @default.
• W2017005150 hasConcept C2776694085 @default.
• W2017005150 hasConcept C2777793932 @default.
• W2017005150 hasConcept C2778332735 @default.
• W2017005150 hasConcept C2779951463 @default.
• W2017005150 hasConcept C2779998722 @default.
• W2017005150 hasConcept C2780739268 @default.
• W2017005150 hasConcept C2781187634 @default.
• W2017005150 hasConcept C44249647 @default.
• W2017005150 hasConcept C526805850 @default.
• W2017005150 hasConcept C71924100 @default.
• W2017005150 hasConceptScore W2017005150C121608353 @default.
• W2017005150 hasConceptScore W2017005150C126322002 @default.
• W2017005150 hasConceptScore W2017005150C143998085 @default.
• W2017005150 hasConceptScore W2017005150C159110408 @default.
• W2017005150 hasConceptScore W2017005150C197934379 @default.
• W2017005150 hasConceptScore W2017005150C207103383 @default.
• W2017005150 hasConceptScore W2017005150C2776694085 @default.
• W2017005150 hasConceptScore W2017005150C2777793932 @default.
• W2017005150 hasConceptScore W2017005150C2778332735 @default.
• W2017005150 hasConceptScore W2017005150C2779951463 @default.
• W2017005150 hasConceptScore W2017005150C2779998722 @default.

• next